

1 TO THE HONORABLE SENATE:

2 The Committee on Health and Welfare to which was referred Senate Bill
3 No. 92 entitled “An act relating to interchangeable biological products”
4 respectfully reports that it has considered the same and recommends that the
5 Senate concur in the House Proposal of Amendment with further proposals of
6 amendment as follows:

7 First: In Sec. 1, 18 V.S.A. § 4601, in subdivision (5)(A), before the
8 semicolon, by inserting as may be reflected in the U.S. Food and Drug
9 Administration’s Lists of Licensed Biological Products with Reference Product
10 Exclusivity and Biosimilarity or Interchangeability Evaluations, sometimes
11 referred to as the “Purple Book”

12 Second: In Sec. 8, 18 V.S.A. § 4636, in subdivision (a)(1), following “in
13 this State”, by inserting for major medical health insurance

14 Third: By adding a reader assistance heading and a new section to be Sec.
15 11a to read as follows:

16 * * * Working Group on Prescription Drug Cost Savings
17 and Price Transparency * * *

18 Sec. 11a. WORKING GROUP ON PRESCRIPTION DRUG COST
19 SAVINGS AND PRICE TRANSPARENCY; REPORT

20 (a) The Secretary of Human Services or designee shall convene a working
21 group comprising one representative each from the Department of Vermont

1 Health Access, the Green Mountain Care Board, the Vermont Board of
2 Pharmacy, the Vermont Association of Chain Drug Stores, the Vermont
3 Pharmacists Association, the Vermont Retail Druggists, Bi-State Primary Care
4 Association, and the Vermont Association of Hospitals and Health Systems to
5 investigate and analyze prescription drug pricing throughout the prescription
6 drug supply chain in order to identify opportunities for savings for Vermont
7 consumers and other payers and for increasing prescription drug price
8 transparency at all levels of the supply chain, including manufacturers,
9 wholesalers, pharmacy benefit managers, health insurers, and consumers.

10 (b) On or before November 15, 2018, the working group shall provide its
11 findings and recommendations to the House Committee on Health Care and the
12 Senate Committee on Health and Welfare.

13
14
15
16
17 (Committee vote: _____)

18 _____

19 Senator _____

20 FOR THE COMMITTEE